US FDA’s Infant Formula Regulatory Authority Doesn’t Reach ‘All That Needs To Be Fixed’
Executive Summary
“This system is fundamentally prone to supply chain disruptions with so few manufacturers,” says Mark Moorman, FDA Office of Food Safety director. In FDLI presentation, he acknowledges delicate balance in stemming distribution of potentially contaminated power formula while sustaining supply.
You may also be interested in...
US Nutritionals Market Q3 Results: Herbalife, Abbott, ChromaDex, USANA, Mannatech
Herbalife’s five sales regions leaving behind pandemic impact at different speeds; Abbott’s 15.5% nutritional sales growth didn’t overcome more than 30% slump in diagnostics sales; ChromaDex steady sales growth for most of past three years continues with 14% in latest quarter; USANA and Mannatech results slump.
Abbott Speaks Lingo Wearables For Future Growth, Posts Formula As Current Consumer Sales Driver
Lingo’s target “is to do something that not a lot of well-established health care companies do, which is to create a product that's really targeting a healthy population and a healthy population that wants to stay healthy,” says CEO Robert Ford.
US FDA Notes Concerns At Multiple Formula Plants After One Linked To Contamination, Shortage
Agency sends letters to manufacturers and other businesses involved in production and distribution “to assist industry in improving the microbiological safety of powdered infant formula.” Information from “routine surveillance inspections” of facilities and “for-cause inspections to follow up on consumer complaints” noted in letters.